Form 4: Silo Pharma CEO Eric Weisblum Reports Stock Purchases
SEC Form 4 Filing
Silo Pharma's CEO, Eric Weisblum, reported purchasing common stock in two transactions on June 11 and June 12, 2024.
Summary
- Eric Weisblum, CEO and President of Silo Pharma, Inc., reported purchasing shares of common stock.
- On June 11, 2024, he acquired 562 shares at a price of $1.08 per share.
- On June 12, 2024, he acquired 4,438 shares at a weighted average price of $1.11 per share, with prices ranging from $1.11 to $1.12.
- Following these transactions, Weisblum directly owns 180,432 shares of Silo Pharma's common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's stock purchase is a positive sign, but it's a relatively small transaction and doesn't provide a comprehensive view of the company's financial health.
Positives
- The CEO's purchase of shares could be interpreted as a positive signal about the company's prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued. However, it's just one factor to consider when evaluating a company's potential.
Key Dates
| Date | Description |
|---|---|
| 06/11/2024 | Eric Weisblum purchased 562 shares of common stock at $1.08 per share. |
| 06/12/2024 | Eric Weisblum purchased 4,438 shares of common stock at a weighted average price of $1.11 per share. |
| 06/13/2024 | Date of signature for the Form 4 filing. |
Keywords
Silo Pharma, Eric Weisblum, stock purchase, Form 4, CEO, common stock, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.